Maravai Lifesciences Holdings, Inc. (DE:MAR)
NASDAQ:MAR
Earnings Data
Report Date
Aug 11, 2026After Close (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
-0.04Last Year’s EPS
-0.07Same Quarter Last Year
Moderate Buy
Based on 5 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call communicated strong operational and financial progress: robust revenue growth (41% YoY), sizable adjusted EBITDA improvement, first positive free cash flow since 2024, raised full-year revenue and EBITDA guidance, product adoption (ModTail) and R&D/IP milestones. Challenges discussed were largely execution and timing related (China/distributor ordering, quarter-to-quarter lumpiness, academic demand weakness) and some near-term limitations from new GMP launches and elevated debt. Overall, positives—driven by mix shift toward higher-margin GMP/discovery consumables, realized cost savings, and improving cash generation—outweigh the highlighted risks.Company Guidance
Strong Top-Line Growth
Total Q1 revenue of $65.8M, up 41% year-over-year; base business revenue (ex-COVID CleanCap) up 10% YoY.
TriLink Outperformance
TriLink revenue grew 65% YoY (base business growth 15% ex-CleanCap), represented 72% of total revenue (64% ex-CleanCap) and generated $17.3M of adjusted EBITDA (improvement of >$26M YoY).
Profitability and Margin Expansion
Adjusted gross margin of 65.3% and adjusted EBITDA of $20.3M in Q1, exceeding expectations and improving by more than $30M YoY.
Cash Flow and Balance Sheet Progress
Generated $4.2M of positive free cash flow (first positive FCF since Q3 2024); quarter-end cash of $165.9M and a voluntary $50M debt prepayment (long-term debt $242.9M post-payment).
Substantially Raised Full-Year Guidance
Raised 2026 revenue guidance to $205M–$215M (growth of 10%–16% vs 2025) and substantially increased adjusted EBITDA guidance to $30M–$32M (improvement of $61M–$63M YoY).
Product and Commercial Momentum
ModTail adoption surpassing 70 customers with repeat orders; GMP funnel strength with GMP customers expected to grow 22% in 2026 (nine RUO→GMP conversions, two already converted).
R&D and IP Progress
TriLink GMP facility completed with GMP enzymes expected to launch this quarter; ModTail GMP expected later in 2026; two additional European patents for TriLink and a new U.S. patent for Cygnus MVP granted in Q1.
Cygnus Profitability
Cygnus generated $13.6M of adjusted EBITDA with strong margins of 73.8%; continued market role with a 100% attach rate supporting safety testing of all 29 FDA/EMA-approved CAR T/gene therapies.
Operational Efficiency Realized
Restructuring actions now expected to deliver >$65M in annual EBITDA savings; digital/e-commerce channel achieved record website revenue and improved order conversion and efficiency.
DE:MAR Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
DE:MAR Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 07, 2026 | €3.28 | €3.18 | -3.05% |
Feb 25, 2026 | €2.70 | €2.96 | +9.63% |
Nov 06, 2025 | €2.48 | €2.46 | -0.81% |
Aug 11, 2025 | €1.73 | €2.26 | +30.64% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Maravai Lifesciences Holdings, Inc. (DE:MAR) report earnings?
Maravai Lifesciences Holdings, Inc. (DE:MAR) is schdueled to report earning on Aug 11, 2026, After Close (Confirmed).
What is Maravai Lifesciences Holdings, Inc. (DE:MAR) earnings time?
Maravai Lifesciences Holdings, Inc. (DE:MAR) earnings time is at Aug 11, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is the P/E ratio of Maravai Lifesciences Holdings, Inc. stock?
The P/E ratio of Maravai Lifesciences Holdings is N/A.
What is DE:MAR EPS forecast?
DE:MAR EPS forecast for the fiscal quarter 2026 (Q2) is -0.04.